The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Konialis, Christopher; Spengos, Konstantinos; Iliopoulos, Panagiotis; Karapanou, Sophia; Gialafos, Elias; Hagnefelt, Birgitta; Vemmos, Konstantinos; Pangalos, Constantinos

doi:10.17219/acem/38841

Cited by 20 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,19 Moreover, ε4 carriers have a 40% higher risk of developing ASCVD where treatment with statins is often ineffective, whereas ε2 carriers have been reported to exhibit a higher lipid-lowering effect with statins. 20,21 At 1 month follow-up of our patients, we observed that the levels of TC and LDL-C were significantly lowered with the same dose of statins, although there were no significant differences between the TG and HDL groups. Therefore, the advantages of statin in lowering cholesterol were consistent with those previously reported.…”

Section: Discussionmentioning

confidence: 66%

Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases

Wang

Zhao

et al. 2021

Ann Acad Med Singap

View full text Add to dashboard Cite

Introduction: Apolipoprotein E (APOE) gene is a promising candidate for the diagnosis of hyperlipoproteinaemia and atherosclerosis. Polymorphisms in APOE have been reported to result in differential efficacies of statins in atherosclerotic cardiovascular diseases. Method: We classified APOE genotypes of 225 patients treated with atorvastatin and analysed the relationship between genotypes and blood lipid levels. Results: The baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly lower in APOE ε4 than APOE ε3 carriers. Levels of TC and LDL-C decreased significantly after 1 month of atorvastatin treatment. Statins have a higher significant effect in reducing TC and LDL-C levels in APOE ε4 genotype. Conclusion: Polymorphism in APOE is related to the efficacy of atorvastatin in reducing the levels of TC and LDL-C. Keywords: Apolipoprotein E, lipid-lowering efficacy, polymorphism, statin, total cholesterol

show abstract

Section: Discussionmentioning

confidence: 66%

Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases

Wang

Zhao

et al. 2021

Ann Acad Med Singap

View full text Add to dashboard Cite

show abstract

“…In contrast, in the largest prospective cohort to date (n = 22,169), APOE genotype was not associated with CHD risk after controlling for a variety of CV risk factors, namely, lipid profile [9]. APOE4 may also be associated with an increased risk of cerebrovascular ischemic events [17, 18].…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study

et al. 2019

View full text Add to dashboard Cite

Background. The apolipoprotein E (APOE) polymorphisms are associated with cardiovascular (CV) disease, but its interaction with type 2 diabetes mellitus (T2DM) long-term incidence is unknown. We investigated the association between APOE genotype and long-term (i) CV events and (ii) T2DM incidence in a Southern European primary prevention cohort. Methods. We assessed individual APOE genotypes in a total of 436 patients followed at a lipid clinic, with a 15-year median follow-up time. We collected data on major CV events (CV death, myocardial infarction, and stroke) and T2DM development. Results. No differences were found regarding major CV event incidence among the different APOE genotypes. However, after excluding 39 patients with a prior history of T2DM, APOE2 carriers displayed a higher incidence of T2DM during follow-up (42.2%) than APOE3 (27.1%) and APOE4 (28.7%) carriers. The age-, sex-, triglycerides-, and statin usage-adjusted OR for T2DM incidence in APOE2 carriers was 1.8 (95%CI 1.1-2.9, p=0.03), compared with wild-type APOE3. To address the role of statins as a confounder, we analyzed T2DM incidence in statin-treated patients. Statin-treated APOE2 carriers also had a higher T2DM incidence (57.9%), in comparison with APOE3 homozygotes (31.6%) and APOE4 carriers (32.5%). After adjustment for confounding, APOE2 carriers on statins displayed a similar twofold increase in T2DM risk compared to APOE3 homozygotes (OR 2.1, 95%CI 1.1-4.0, p=0.03). Conclusion. Our findings suggest a twofold increase in T2DM incidence in APOE2 carriers. This may prompt for a specific glucose dysmetabolism follow-up that might be tailored on the APOE genotype.

show abstract

“…Ê íàñòîÿùåìó âðåìåíè, íà îñíîâàíèè äàííûõ øèðîêîãåíîìíûõ èññëåäîâàíèé àññîöèàöèé (GWAS) è ïîèñêà àññîöèàöèé ñ èñïîëüçîâàíèåì àíàëèçà êàíäèäàòíûõ ãåíîâ, óñòàíîâëåíî, ÷òî ïîëèìîðôíûå âàðèàíòû APOE ÿâëÿþòñÿ ôàêòîðàìè ðèñêà ñåðäå÷íî-ñîñóäèñòûõ çàáî-ëåâàíèé, áîëåçíè Àëüöãåéìåðà (ÁÀ), âíîñÿò âêëàä â ôåíîìåí äîëãîaeèòåëüñòâà [6][7][8][9][10][11].…”

Section: ââåäåíèåunclassified

“…Íîñèòåëè àëëåëÿ e4 îáëàäàþò â ñðåäíåì ïîíèaeåííûì çíà÷åíèåì ñóììàðíîãî áàëëà ÌîÑÀ. Ýòîò àëëåëü ÿâëÿåòñÿ ïðåäðàñïîëàãàþùèì ê èíôàðêòó ìèîêàðäà [8], ÁÀ [9,24], íåáëàãîïðèÿòåí äëÿ äîñòèaeåíèÿ âîçðàñòà äîëãîaeèòåëüñòâà â àáõàçñêîé ïîïóëÿöèè [10], è â òî aeå âðåìÿ åãî íîñèòåëè ïðîÿâëÿþò ñíèaeåííûå êîãíèòèâíûå ñïîñîáíîñòè â ïîaeèëîì âîçðàñòå (21,39 ± 4,21 è 22,37 ± 3,79 ó íîñèòåëåé e4 ïðîòèâ îñòàëüíûõ ãåíîòèïîâ ñîîòâåòñòâåííî).…”

Section: ðåçóëüòàòû è îáñóAeäåíèåunclassified

Association of apolipoprotein E gene polymorphism with cognitive abilities variability of elderly people

Марусин¹,

Makeeva²,

Вагайцева³

et al. 2018

Nauchno-Prakticheskii Zhurnal «Medicinskaia Genetika»

View full text Add to dashboard Cite

Physiological changes in the brain with natural aging and the development of dementia have a common genetic basis, which makes it important to search for genetic variants that delineate the natural decline in cognitive abilities with age and dementia of the Alzheimer’s type. Objective: the search for the relationship between two polymorphic variants (rs429358 and rs7412) APOE gene and their protein isoforms (apoE) with the variability of cognitive functions in the elderly, determined by Montreal Cognitive Assessmnet (MoCA) total score. The study was performed on a group of 695 elderly people (177 men and 518 women) tested by a battery of MoCA tests. Genotyping was carried out by real-time PCR using TaqMan probes. The analysis of genotypic variability associations with the nominal trait was performed by the Kruskel-Wallis and the median test nonparametric methods.It was shown that the rs429358*C allele carriers and protein isoforms e4/e4+e2/e4+e3/e4 carriers in comparison with the e3/e3 homozygous have the greatest risk of decreased cognitive abilities in old age (OR (95% CI) was 1.51 (1.09 - 2.10), c = 6.66, p = 0.01 and OR = 1.64, 95% CI (1.11 - 2.44), c = 6.76, p = 0.009, respectively). Probably, the revealed associations indicate to the presence of common genes and mechanisms for dementia and intellect with normal variability of cognitive functions inheritance.

show abstract

The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers

Cited by 20 publications

References 24 publications

Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases

Association of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases

Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study

Association of apolipoprotein E gene polymorphism with cognitive abilities variability of elderly people

Contact Info

Product

Resources

About